TMCnet News
Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDOLYON, France and CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 10th International Congress of the Growth Hormone Research Society (GRS), which is being held May 10-11 in Stockholm, Sweden, the 26th European Congress of Endocrinology (ECE), which is being held May 11-14 in Stockholm, Sweden, and at the 2024 Endocrine Society Meeting (ENDO), which is being held June 1-4 in Boston, Massachusetts. These presentations cover both of Amolyt’s development programs, eneboparatide in Phase 3 for the treatment of hypoparathyroidism and AZP-3813 in Phase 1 for the treatment of acromegaly. Details of the presentations are as follows: 10th International Congress of the Growth Hormone Research Society (GRS) – May 10-11, Stockholm, Sweden Title: Additive Effect of Combined Treatment with the Small Peptide GH Receptor Antagonist, AZP-3813, and the Somatostatin Analog, Octreotide, in Decreasing IGF1 Levels in the Rat 26th European Congress of Endocrinology (ECE) – May 11-14, Stockholm, Sweden Title: Renal Complications in Chronic Hypoparathyroidism Title: A Translational Approach to Investigate the Mechanism Whereby Eneboparatide Induces Prolonged Calcium Normalization in Patients with Chronic Hypoparathyroidism Title: Increased Urinary Excretion of Calcium and Nephrolithiasis: Real-Life Data from the Epi-Hypo Cohort of Hypoparathyroidism Patients Title: Remaining Secretion of Parathyroid Hormone Is Associated with Calcium Excretion in Chronic Hypoparathyroidism Time: 2:40-3:40 p.m. CEST Title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel, Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects Title: Additive Effect of Combined Treatment with the Small Peptide GH Receptor Antagonist, AZP-3813, and the Somatostatin Analog, Octreotide, in Decreasing IGF1 Levels in the Rat Title: Increased Bone Fragility Over Time in Women with Chronic Hypoparathyroidism: Real-world Data from the HypoparaNet Italian Cohort 2024 Endocrine Society Meeting (ENDO) – June 1-4, Boston, Mass. Title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects Title: Skeletal Effects Among Pre and Postmenopausal Women with Hypoparathyroidism (HypoPT); Data from the Canadian National Hypoparathyroidism Registry (CNHR) Title: Increased Fragility of Bone Over Time in Female Patients with Chronic Hypoparathyroidism: Real-world Data from the Italian Cohort Title: Enhanced Ability of the Small Peptide GH Receptor Antagonist, AZP-3813, to Decrease IGF1 When Combined with the Somatostatin Analog, Octreotide Title: Eneboparatide, a Potent Stimulator of Urinary Calcium Reabsorption, Induces Prolonged Renal Cortex Retention and PTH1 Receptor Signalling About Amolyt Pharma Media Inquiries: Investors Inquiries:
|